LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Latigo Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 3, 2026
$14.30+0.30 (+2.14%)
Close on Oct 19, 2026
- Market cap
- $13.37M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Dividends
Latigo Biotherapeutics has not reported a dividend
No dividend per share appears in Latigo Biotherapeutics's annual filings since fiscal 2024.